Free Newsletter
Medicines Co. still fighting for Angiomax patent
Free newsletter via e-mail
Tools
In spite of a third rejection from the U.S. Patent Office, Medicines Co. CEO Clive Meanwell says he will pursue all options to extend its exclusive rights to the anticoagulant drug Angiomax that accounts for 95 percent of the company's revenue. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: